half-life raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-13. Anything still debated is marked as such rather than presented as settled.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
A pi helix (or π-helix) is a type of secondary structure found in proteins. Discovered by crystallographer Barbara Low in 1952 and once thought to be rare, short π-helices are found in 15% of known protein structures and are believed to be an evolutionary adaptation derived by the insertion of a single amino acid into an α-helix. Because such insertions are highly destabilizing, the formation of π-helices would tend to be selected against unless it provided some functional advantage to the protein. π-helices therefore are typically found near functional sites of proteins.
One reason that conservation equations frequently occur in physics is Noether's theorem. This states that whenever the laws of physics have a continuous symmetry, there is a continuity equation for some conserved physical quantity. The three most famous examples are:
==== Hermaphroditism ==== Some teleost species are hermaphroditic, which can come in two forms: simultaneous and sequential. In the former, both spermatozoa and eggs are present in the gonads. Simultaneous hermaphroditism typically occurs in species that live in the ocean depths, where potential mates are sparsely dispersed. Self-fertilisation is rare and has only been recorded in two species, Kryptolebias marmoratus and Kryptolebias hermaphroditus. With sequential hermaphroditism, individuals may function as one sex early in their adult life and switch later in life. Species with this condition include parrotfish, wrasses, sea basses, flatheads, sea breams and lightfishes. Protandry is when an individual starts out male and becomes female while the reverse condition is known as protogyny, the latter being more common. Changing sex can occur in various contexts. In the bluestreak cleaner wrasse, where males have harems of up to ten females, if the male is removed the largest and most dominant female develops male-like behaviour and eventually testes. If she is removed, the next ranking female takes her place. In the species Anthias squamipinnis, where individuals gather into large groups and females greatly outnumber males, if a certain number of males are removed from a group, the same number of females change sex and replace them. In clownfish, individuals live in groups and only the two largest in a group breed: the largest female and the largest male. If the female dies, the male switches sexes and the next largest male takes his place.
=== Self-administration === As opposed to intramuscular or intravenous injections, subcutaneous injections can be easily performed by people with minor skill and training required. The injection sites for self-injection of medication are the same as for injection by a healthcare professional, and the skill can be taught to patients using pictures, videos, or models of the subcutaneous tissue for practice. People who are to self-inject medicine subcutaneously should be trained how to evaluate and rotate the injection site if complications or contraindications arise. Self-administration by subcutaneous injection generally does not require disinfection of the skin outside of a hospital setting as the risk of infection is extremely low, but instead it is recommended to ensure that the site and person's hands are simply clean prior to administration.
Sources: en.wikipedia.org
== Mechanism of action == Lebrikizumab blocks interleukin 13 (IL-13), a cytokine (cell-signalling protein) that is produced by a type of white blood cell called Th2 cells. IL-13 is thought to induce the expression of another signalling protein, periostin, by epithelial cells of the bronchi. Periostin in turn seems to partake in a number of asthma related problems, such as bronchial hyperresponsiveness, inflammation, and activation and proliferation of airway fibroblasts, which are involved in airway remodelling. This theory is supported by the fact that people with high periostin levels responded significantly better to lebrikizumab in the phase II study: the forced expiratory volume in 1 second (FEV1) was 8.2% higher than under placebo in this group (measured from the respective baselines), while low-periostin participants had 1.6% higher FEV1, and the average value for all participants was 5.5%. The FEV1 increase in low-periostin participants was not statistically significant.
Chain Home radar installations were normally composed of two sites. One compound contained the transmitter towers with associated structures, and a second compound, normally within a few hundred metres distance, contained the receiver masts and receiver equipment block where the operators (principally WAAF, Women's Auxiliary Air Force) worked. The CH system was, by modern terminology, a "bistatic radar", although modern examples normally have their transmitters and receivers far more widely separated. The transmitter antenna consisted of four steel towers 360 feet (110 m) tall, set out in a line about 180 feet (55 m) apart. Three large platforms were stationed on the tower, at 50, 200 and 350 feet off the ground. A 600 ohm transmission cable was suspended from the top platform to the ground on either side of the platform (only on the inside of the end towers). Between these vertical feed cables were the antennas proper, eight half-wave dipoles strung between the vertical cables and spaced ½ of a wavelength apart. They were fed from alternating sides so the entire array of cables was in-phase, given their ½ wavelength spacing. Located behind each dipole was a passive reflector wire, spaced 0.18 wavelength back. The resulting curtain array antenna produced a horizontally polarised signal that was directed strongly forward along the perpendicular to the line of the towers. This direction was known as the line of shoot, and was generally aimed out over the water.
=== Sources === Fulbrook, Mary (1991). A Concise History of Germany. Cambridge University Press. ISBN 978-0-521-36836-0. Murdoch, Adrian (2004). "Germania Romana". In Murdoch, Brian; Read, Malcolm (eds.). Early Germanic Literature and Culture. Boydell & Brewer. pp. 55–73. ISBN 1-57113-199-X.
Sources: en.wikipedia.org
The gabapentinoids are 3-substituted derivatives of GABA; hence, they are GABA analogues, as well as γ-amino acids. Specifically, pregabalin is (S)-(+)-3-isobutyl-GABA, phenibut is 3-phenyl-GABA, and gabapentin is a derivative of GABA with a cyclohexane ring at the 3 position (or, somewhat inappropriately named, 3-cyclohexyl-GABA). Recently, a detailed three dimensional molecular structure of the α2δ-1 protein with gabapentin and alternatively with L-leucine bound at the gabapentinoid binding site has been published PDB: 8FD7. These show that drugs bind to the first calcium channel and chemotaxis (Cache) domain in the α2 part of the α2δ-1. A very similar study shows the structure of α2δ-1 structure with mirogabalin bound. These studies also suggests that the L-leucine bound structure is slightly different than the drug bound structure, consistent with L-leucine acting as an antagonist to gabapentinoid drugs. The gabapentinoids also closely resemble the α-amino acids L-leucine and L-isoleucine, and this may be of greater relevance in relation to their pharmacodynamics than their structural similarity to GABA.
Metenolone, or methenolone, is an androgen and anabolic steroid (AAS) which is used in the form of esters such as metenolone acetate (brand name Primobolan, Nibal) and metenolone enanthate (brand name Primobolan Depot, Nibal Injection). Metenolone esters are used mainly in the treatment of anemia due to bone marrow failure. Metenolone acetate is taken by mouth, while metenolone enanthate is given by injection into muscle. Side effects of metenolone esters include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire. Metenolone esters are synthetic androgens and anabolic steroids and hence are agonists of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). They have moderate anabolic effects and weak androgenic effects, as well as no estrogenic effects or risk of liver damage. Metenolone esters are androgen esters and prodrugs of metenolone in the body. Metenolone esters were introduced for medical use in the early 1960s. In addition to their medical use, metenolone esters are used to improve physique and performance. The drugs are controlled substances in many countries and so non-medical use is generally illicit. They have mostly been discontinued for medical use and have limited availability.
Soldiers were expected to carry their grain rations and cooking utensils in addition to their weaponry, with their backpacks potentially weighing as much as eighty pounds (36 kg). Without the hindrance of oxen and carts, this enabled Macedonian armies to move faster than their opponents. The grain provided to Macedonian soldiers would be wheat, barley, or millet, which were available throughout Asia and could be stored indefinitely when dried. The soldiers would use grinding mills carried by servants to turn the grain into flour, which could then be made into bread, biscuits, and porridge. They also ate various kinds of dried fruits such as dates and figs, which were readily available throughout much of Asia. Whenever possible, they would eat dried meat, salted fish, and shellfish. In ancient China, soldiers of the Han dynasty ate primarily millet and other grains such as wheat, rice, sorghum, etc. Grains could be eaten as a porridge, boiled, made into a bread or flatbread, smashed and fried in a manner similar to modern fried rice and fried noodles, etc. According to Zhao Chongguo, a military commander of the Han dynasty who served in the first century BC, a force of 10,281 men required 27,363 hu of grain and 308 hu of salt each month, requiring a convoy of 1,500 carts for transport. One hu is equivalent to 19.968 liters, meaning that each soldier would have required 51.9 liters of grain and 0.6 liters of salt per month. Another document at Juyan suggests 3.2 hu, or 63.8 liters, of grain.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.